Danish biotechnology company Genmab announced on Monday that it plans to acquire Dutch firm Merus for $8 billion, in a move aimed at strengthening its oncology pipeline. Merus has developed a promising treatment for head and neck cancer.
Genmab’s Chief Executive Officer, Jan van de Winkel, stated in a release: “This acquisition has the potential to significantly accelerate our evolution into a global biotechnology leader.”
Merus’ petosemtamab is currently in Phase 3 clinical development and is expected to reach the market by 2027. According to van de Winkel, it:
- “Has the potential to be a transformational therapy for patients living with head and neck cancer.”
The Danish group projects that petosemtamab could contribute at least $1 billion in annual sales by 2029, with multi-billion-dollar revenue potential thereafter.
| Feature | Details |
| Drug Name | Petosemtamab |
| Target | Head and neck cancer |
| Development Stage | Phase 3 |
| Expected Market Launch | 2027 |
| Projected Sales | $1 billion by 2029; multi-billion potential later |
Genmab also markets Darzalex, a therapy for multiple myeloma, a type of bone marrow cancer. Darzalex is currently sold in partnership with Johnson & Johnson.
The Merus acquisition represents a strategic step for Genmab to expand its global presence in oncology and bolster its pipeline with innovative cancer treatments.
